Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus ZYRTEC HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE VC W CODEINE versus ZYRTEC HIVES.
PROMETHAZINE VC W/ CODEINE vs ZYRTEC HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist inhibiting ascending pain pathways and altering pain perception. Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, suppresses cough reflex via central action, and has anticholinergic, sedative, and antiemetic effects. Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction of nasal blood vessels, reducing congestion.
Selective histamine H1-receptor antagonist. Inhibits histamine-mediated vasodilation, capillary permeability, and smooth muscle contraction.
1-2 tablets orally every 4-6 hours as needed for cough and congestion. Maximum 12 tablets in 24 hours.
For chronic idiopathic urticaria, adults: 10 mg orally once daily. For intermittent symptoms, up to 10 mg once daily as needed.
None Documented
None Documented
Promethazine: 9-16 hours (range 7-20 hours) in adults; codeine: 2.5-3.5 hours (terminal) with clinical considerations for prolonged effects in hepatic impairment and CYP2D6 poor metabolizers.
The terminal elimination half-life is approximately 8.3 hours in healthy adults. In patients with renal impairment (CrCl < 40 mL/min), half-life can extend to 18–21 hours, necessitating dose adjustment.
Renal: 70-80% as unchanged promethazine and metabolites (including codeine and its glucuronides); biliary/fecal: 10-20%.
Cetirizine is primarily excreted renally as unchanged drug (approximately 70%). Fecal excretion accounts for about 10%. The remainder undergoes hepatic metabolism to inactive metabolites, which are also renally eliminated.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine